GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » 14-Day RSI

Evelo Biosciences (Evelo Biosciences) 14-Day RSI : 50.01 (As of May. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-08), Evelo Biosciences's 14-Day RSI is 50.01.

The industry rank for Evelo Biosciences's 14-Day RSI or its related term are showing as below:

EVLO's 14-Day RSI is ranked worse than
53.68% of 1574 companies
in the Biotechnology industry
Industry Median: 49.075 vs EVLO: 50.01

Competitive Comparison of Evelo Biosciences's 14-Day RSI

For the Biotechnology subindustry, Evelo Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evelo Biosciences's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's 14-Day RSI falls into.



Evelo Biosciences  (OTCPK:EVLO) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evelo Biosciences  (OTCPK:EVLO) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Evelo Biosciences 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Evelo Biosciences (Evelo Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Executives
Simba Gill director, officer: President & CEO 515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer officer: See Remarks C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell officer: Chief Financial Officer 1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale officer: Chief Medical Officer C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp 10 percent owner 312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere officer: Principal Accounting Officer
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139